(while the site is loading)
  • Engineering novel biotherapeutics
    for a healthier tomorrow.
  • Protein drugs
    Engineered not discovered.
  • Engineering novel biotherapeutics
    for a healthier tomorrow.

Our mission:

The right drug to the right cell

We use computational tools to enable peptide ligands which are 100x more drug-like and specific than natural ligands. This enables the next generation of therapeutic applications with a focus on next generation therapeutic payloads (nucleotides, siRNA, radioisotopes, etc.) delivered with de-novo peptides.

ProteinQure has built a world-class computational platform for peptide drug discovery, combining high-performance computing, molecular simulations and machine learning to design and optimize small exotic peptide therapeutics. These physics-based methods enable the structure-based design of novel ligands and make us less dependent on large data sets. We routinely work with less than 100 experimental data points for lead optimization.

We have three collaborations with top 25 pharma companies and have successfully validated our compounds in their experimental assays. We use our computational platform as well as wetlab validation to solve our drug design challenges and are now beginning to develop an internal pipeline.

ibm quantum computer

De-novo hits

We engineer hits which are novel chemical entities. Peptides are one of the fastest growing classes of therapeutics with applications across all major disease indications. Our platform is designed to iterate with experimental results to save you money and time.

mathematics whiteboard

Property optimization

We perform iterative optimization of therapeutic leads to preserve properties like binding affinity, selectivity, stability and solubility. This multi-parameter optimization requires a search over vast areas of sequence space.

multiparameter optimization landscape

Library design

We own proprietary structure-biased libraries based on display methods that we can screen. We also work with partners to create custom computationally designed libraries to incorporate specific constraints and motifs.


Despite their inherent advantages, it is very difficult to design protein-based therapeutics. Computational tools have been previously held back because of proteins' larger size and the lack of available structural data. We leverage physics-based methods and novel machine learning algorithms to overcome these challenges.

protein therapeutics scale

Peptide advantages for drug delivery

Tissue specificity and penetration

By choosing tissue-restricted targets which undergo internalization, we ensure that the therapeutic payload is going to the right cells. Their small size also enhances tissue penetration.

Redosable and tolerable

Peptides can be engineered to be non-immunogenic by design, we can also achieve an unprecedented range of necessary PK profiles.

Flexible building blocks

Peptide conjugates are much easier to manufacture. Novel chemistries allow for a wide range of conjugations and they can succeed in many routes of administration.

selected publications

Selected customers

The combination of designed peptide libraries, based on ProteinQure’s computational methods, with our advanced capabilities in display technologies will help us harness the potential of this therapeutic class.

Tristan Vaughan, VP of Antibody Discovery & Protein Engineering, AstraZeneca

Our Address

We are located in downtown Toronto; one of the fastest growing tech hubs in North America. At the heart of the university and life sciences ecosystems, we benefit from great relationships with the surrounding players in AI and biotech.

ProteinQure - Designing a healthier tomorrow

Interested in learning more? Come talk to us!

Office Address: 119 Spadina Ave Suite 304, Toronto, ON M5V 2L1, Canada



Show Google Map

Drop us a Message

Drop us a message

You want to know more? Feel free to drop us a message!

Or see contact page
Validation error occured. Please enter the fields and submit it again.
Thank You ! Your email has been delivered.